Candidate vaccine for prostate cancer fails

Country

Sweden

A peptide vaccine intended to prevent disease progression in patients with prostate cancer failed to show efficacy in a Phase 2b study despite promising data earlier in its development. The vaccine, RV001 (onilcamotide) was developed by RhoVac AB of Sweden which announced the study results on 30 May.